Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

Diagnostic Microbiology and Infectious Disease

Volumn 36, Issue 1, 2000, Pages 19-36

  Gales, Ana C ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 TERT BUTYLGLYCYLAMIDOMINOCYCLINE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; MINOCYCLINE; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TROVAFLOXACIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; BACTEROIDES FRAGILIS; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; CORYNEBACTERIUM; ENTEROBACTERIACEAE; ENTEROCOCCUS; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SENSITIVITY AND SPECIFICITY; TETRACYCLINES;

EID: 0033954848     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00092-9     Document Type: Article

References (36)

1. Anonymous. Recommendations for perventing the spread of vancomycin-resistance recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC) . Morb Mortal Wkly Rep. 44:(RR-12):1995;1-13.
2. Bergeron J., Ammirati M., Danley D., James L., Norcia M., Retsama J., Strik C.A., Su W.G., Sutcliffe J., Wondrock L. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet (m)- and Tet (o)-mediated ribosomal protection. Antimicrob Agents Chemother. 40:1996;2226-2228.
3. Chopra I., Hawkey P.M., Hinton M. Tetracyclines, molecular, and clinical aspects. J Antimicrob Chemother. 29:1992;245-277.
4. Doern G.V., Pfaller M.A., Kugler K., Freeman J., Jones R.N. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America 1997 results from the SENTRY Antimicrobial Surveillance Program . Clin Infect Dis. 27:1998;764-770.
5. Eliopoulos G.M., Wennersten C.B., Cole G., Moellering R.C. In vitro activities of two glycylcyclines against Gram-positive bacteria. Antimicrob Agents Chemother. 38:1994;534-541.
6. Fraise A.P., Brenwald N., Andrews J.M., Wise R. In vitro activity of two glycylcyclines against enterococci resistant to other agents. J Antimicrob Chemother. 35:1995;877-881.
7. Goldstein F.W., Kitzis M.D., Acar J.F. N,N-Dimethylclycyl-amido derivative of minocycline and 6-demethyl-6-desoxytetracycline, two new glycylcyclines highly effective against tetracycline-resistant Gram-positive. Antimicrob Agents Chemother. 38:1994;2118-2120.
8. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-146.
9. Johnson D.M., Jones R.N. Two investigational glycylcyclines, DMG-DMDOT and DMG-MINO antimicrobial activity studied against Gram-positive species. Diagn Microbiol Infect Dis. 24:1996;53-57.
10. Jones R.N., Ballow C.H., Biedenbach D.J., Deinhart J.A., Schentag J.J. Antimicrobial activity of quinupristin/dalfopristin (RP 59500, Synercid™) tested against over 28, 000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis. 30:1998;437-451.
11. Jones R.N., Johnson D.M., Erwin M.E. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother. 40:1996;720-726.
12. Jones R.N., Low D.E., Pfaller M.A. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria the role of streptogramins and other newer compounds . Diagn Microbiol Infect Dis. 33:1999;101-112.
13. Quality Control Study Group , Jones R.N., Marshall S.A., Erwin M.E. Antimicrobial activity and spectrum of SCH 27899 (Ziracin™) tested against Gram-positive species including recommendations for routine susceptibility testing methods and quality control. Diagn Microbiol Infect Dis. 34:1999;103-110.
14. Kenny G.E., Cartwright F.D. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureplasma urealyticum to new glycylcyclines in comparison with older tetracyclines. Antimicrob Agents Chemother. 38:1994;2628-2632.
15. Levy S.B. Evolution and spread of tetracycline resistance determinants. J Antimicrob Chemother. 24:1989;1-3.
16. Quality Control Study Group , Marshall S.A., Jones R.N., Erwin M.E. Antimicrobial activity of SCH27899 (Ziracin™), a novel everninomicin derivative, tested against Streptococcus spp. disk diffusion/Etest method evaluations and quality control guidelines . Diagn Microbiol Infect Dis. 33:1999;19-25.
17. thInterscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. Sept. 24-27, p. 266.
18. Mojumdar M., Khan S.A. Characterization of the tetracycline resistance gene of plasmid pT181 Staphylococcus aureus. J Bacteriol. 170:1988;5522-5528.
19. Murry L., Park B.H., Burdett V., Levy S.B. Energy dependent efflux mediated by Class L (tet L) tetracycline resistance determinant from streptococci. Antimicrob Agents Chemother. 31:1987;1648-1651.
20. th ed. Wayne, PA: NCCLS.
21. th ed. Wayne, PA: NCCLS.
22. National Committee for Clinical Laboratory Standards (NCCLS). (1999). Performance standards for antimicrobial susceptibility testing: M100-S9. Wayne, PA: NCCLS.
23. Nord C.E., Lindmark A., Persson I. In vitro activity of DMG-MINO and DMG-DOT, two new glycylcyclines, against anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 12:1993;784-786.
24. Oliva B., Gordon G., McNicholas P., Ellestad G., Chopra I. Evidence that tetracyclines analogs whose primary target is not the bacterial ribosome cause lysis of Escherichia coli. Antimicrob Agents Chemother. 36:1992;913-919.
25. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. Sept 24-27, p. 266.
26. SENTRY Participants Group , Pfaller M.A., Jones R.N., Doern G.V., Sader H.S., Kugler K., Beach M. Survey of blood stream infections attributable to Gram-positive cocci Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program . Diagn Microbiol Infect Dis. 33:1999;283-297.
27. Rasmussen B.A., Gluzman Y., Tally F.P. Inhibition of protein synthesis occurring on tetracycline-resistant, tet-M protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother. 38:1994;1658-1660.
28. Speer B.S., Shoemaker N.B., Salyers A.A. Bacterial resistance to tetracyclines mechanisms, transfer, and clinical significance . Clin Microbiol Rev. 5:1992;387-399.
29. Sum P.E., Lee V.J., Testa R.T., Hlavka J.J., Ellestad G.A., Bloom J.D., Gluzman Y., Tally F.P. Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J Med Chem. 37:1994;184-188.
30. Testa R.T., Petersen P.F., Jacobs N.V., Sum P.E., Lee V.J., Tally F.P. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother. 37:1993;2270-2277.
31. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. Sept 24-27, p. 266.
32. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. Sept 24-27, p. 266.
33. Weiss W.J., Jacobus N.V., Petersen P.F., Testa R.T. Susceptibility of enterococci, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae to the glycylcyclines. J Antimicrob Chemother. 36:1995;225-230.
34. thInterscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. Sept 24-27, p. 267.
35. Wise R., Andrews J.M. In vitro activities of two glycylcyclines. Antimicrob Agents Chemother. 38:1994;1096-1102.
36. Yuk J.H., Dignani C., Harris R.L., Bradshaw M.W., Williams T.W. Jr. Minocycline as an alternative antistaphylococcal agent. Rev Infect Dis. 13:1991;1023-1024.